DelveInsight’s, “T-cell Malignancies Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 82+ pipeline drugs in T-cell Malignancies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our latest breakthroughs in T-Cell Malignancies research. Learn more about our innovative pipeline today! @ T-Cell Malignancies Pipeline Outlook

 

Key Takeaways from the T-Cell Malignancies Pipeline Report

• DelveInsight’s T-cell Malignancies pipeline report depicts a robust space with 80+ active players working to develop 82+ pipeline therapies for T-cell Malignancies treatment.
• The leading T-cell Malignancies Companies such as AB Science, Corvus Pharmaceuticals, Bristol-Myers Squibb, Kymera Therapeutics, neoX Biotech, Jiangsu Hengrui Medicine, Soligenix, Equillium, Janssen Biotech, Ono Pharmaceutical, Artiva Biotherapeutics, Dialectic Therapeutics, Nutcracker Therapeutics, FutureGen Biopharmaceutical, Step Pharma, Merck & Co, and others.
• Promising T-cell Malignancies Therapies such as Masitinib, Soquelitinib, Golcadomide, KT-333, NXD02, and others.
• This segment of the T-cell Malignancies pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand T-cell Malignancies clinical trials details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Stay informed about the cutting-edge advancements in T-cell Malignancies treatments. Download for updates and be a part of the revolution in cancer care @ T-cell Malignancies Clinical Trials Assessment

 

T-cell Malignancies Emerging Drugs Profile

 

• Masitinib: AB Science

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with T-cell malignancies.

• Soquelitinib: Corvus Pharmaceuticals

Soquelitinib (formerly known as CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with T-cell malignancies.

• Golcadomide: Bristol-Myers Squibb

Golcadomide is a novel, oral CELMoD agent representing one of several compelling assets generated from our differentiated targeted protein degradation research platform. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with T-cell malignancies.

• KT-333: Kymera Therapeutics

KT-333 is a potent, highly selective degrader of STAT3 in development for the treatment of multiple STAT3-dependent pathologies, including hematological malignancies and solid tumors. STAT3 is an undrugged transcription factor activated through a variety of different cytokine and growth factor receptors via Janus kinases (JAKs), as well as through oncogenic fusion proteins and mutations in STAT3 itself. In certain malignant cells, STAT3 activation is set into overdrive, leading to a dampened immune response, tumor progression, and metastasis. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with T-cell malignancies.

• NXD02: neoX Biotech

NeoX developed NXD02, to improve the therapeutic window by mitigating platelet toxicity through neoX’s AI-empowered degrader design platform, neoDegrader. The drug is currently in the Preclinical stage of development for the treatment of patients with T-cell Malignancies.

 

Learn more about T-cell Malignancies Drugs opportunities in our groundbreaking T-cell Malignancies research and development projects @ T-cell Malignancies Unmet Needs

 

T-cell Malignancies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

T-cell Malignancies Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Discover the latest advancements in T-cell Malignancies treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ T-Cell Malignancies Market Drivers and Barriers, and Future Perspectives

 

Scope of the T-cell Malignancies Pipeline Report

• Coverage- Global
• T-cell Malignancies Companies- AB Science, Corvus Pharmaceuticals, Bristol-Myers Squibb, Kymera Therapeutics, neoX Biotech, Jiangsu Hengrui Medicine, Soligenix, Equillium, Janssen Biotech, Ono Pharmaceutical, Artiva Biotherapeutics, Dialectic Therapeutics, Nutcracker Therapeutics, FutureGen Biopharmaceutical, Step Pharma, Merck & Co, and others.
• T-cell Malignancies Therapies- Masitinib, Soquelitinib, Golcadomide, KT-333, NXD02, and others.
• T-cell Malignancies Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• T-cell Malignancies Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of T-cell Malignancies Pipeline on our website @ T-cell Malignancies Emerging Drugs and Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. T-cell Malignancies: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. T-cell Malignancies– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Masitinib: AB Science
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Soquelitinib: Corvus Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. KT-333: Kymera Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. NXD02: neoX Biotech
18. Drug profiles in the detailed report…..
19. Inactive Products
20. T-cell Malignancies Key Companies
21. T-cell Malignancies Key Products
22. T-cell Malignancies- Unmet Needs
23. T-cell Malignancies- Market Drivers and Barriers
24. T-cell Malignancies- Future Perspectives and Conclusion
25. T-cell Malignancies Analyst Views
26. T-cell Malignancies Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/